JP2006504723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006504723A5 JP2006504723A5 JP2004542620A JP2004542620A JP2006504723A5 JP 2006504723 A5 JP2006504723 A5 JP 2006504723A5 JP 2004542620 A JP2004542620 A JP 2004542620A JP 2004542620 A JP2004542620 A JP 2004542620A JP 2006504723 A5 JP2006504723 A5 JP 2006504723A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- gemcitabine
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 6
- 229960005277 gemcitabine Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000001093 anti-cancer Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 230000001772 anti-angiogenic effect Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 230000002137 anti-vascular effect Effects 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0223380.7 | 2002-10-09 | ||
| GBGB0223380.7A GB0223380D0 (en) | 2002-10-09 | 2002-10-09 | Combination therapy |
| PCT/GB2003/004334 WO2004032937A1 (en) | 2002-10-09 | 2003-10-06 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010287659A Division JP2011088921A (ja) | 2002-10-09 | 2010-12-24 | 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006504723A JP2006504723A (ja) | 2006-02-09 |
| JP2006504723A5 true JP2006504723A5 (enExample) | 2006-11-24 |
| JP5416328B2 JP5416328B2 (ja) | 2014-02-12 |
Family
ID=9945538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004542620A Expired - Fee Related JP5416328B2 (ja) | 2002-10-09 | 2003-10-06 | 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 |
| JP2010287659A Pending JP2011088921A (ja) | 2002-10-09 | 2010-12-24 | 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010287659A Pending JP2011088921A (ja) | 2002-10-09 | 2010-12-24 | 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060009418A1 (enExample) |
| EP (1) | EP1551409B1 (enExample) |
| JP (2) | JP5416328B2 (enExample) |
| KR (1) | KR101098061B1 (enExample) |
| CN (1) | CN100363004C (enExample) |
| AT (1) | ATE357236T1 (enExample) |
| AU (1) | AU2003269253B2 (enExample) |
| BR (1) | BR0315088A (enExample) |
| CA (1) | CA2501651C (enExample) |
| CY (1) | CY1106601T1 (enExample) |
| DE (1) | DE60312715T2 (enExample) |
| DK (1) | DK1551409T3 (enExample) |
| ES (1) | ES2282656T3 (enExample) |
| GB (1) | GB0223380D0 (enExample) |
| IL (1) | IL167633A (enExample) |
| MX (1) | MXPA05003595A (enExample) |
| NO (1) | NO330601B1 (enExample) |
| NZ (1) | NZ538999A (enExample) |
| PT (1) | PT1551409E (enExample) |
| SI (1) | SI1551409T1 (enExample) |
| WO (1) | WO2004032937A1 (enExample) |
| ZA (1) | ZA200502753B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1676845B1 (en) | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| EP1274692B1 (en) | 2000-04-07 | 2006-08-02 | AstraZeneca AB | Quinazoline compounds |
| HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| NZ534171A (en) | 2002-02-01 | 2007-06-29 | Astrazeneca Ab | Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| NZ539408A (en) | 2002-11-04 | 2007-09-28 | Astrazeneca Ab | Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| BRPI0412426A (pt) * | 2003-07-10 | 2006-09-05 | Astrazeneca Ab | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| WO2007003933A2 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
| WO2007014335A2 (en) * | 2005-07-27 | 2007-02-01 | The University Of Texas System | Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| EP1971338B8 (en) * | 2005-12-22 | 2011-09-21 | AstraZeneca AB | Combination of zd6474 and pemetrexed |
| ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| US20100092466A1 (en) * | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
| AU2008205847A1 (en) | 2007-01-19 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
| KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| RU2580609C2 (ru) | 2011-04-18 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| WO2014185540A1 (en) | 2013-05-14 | 2014-11-20 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| KR20250024102A (ko) | 2015-02-25 | 2025-02-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| CN106619688A (zh) * | 2016-12-27 | 2017-05-10 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的药物组合物及应用 |
| CN106727657A (zh) * | 2016-12-27 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的西药组合物及应用 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US20200197384A1 (en) | 2017-05-16 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE92499T1 (de) * | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP1676845B1 (en) * | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US6953679B2 (en) * | 2000-09-19 | 2005-10-11 | Bristol-Myers Squibb Company | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| EP1534287A1 (en) * | 2002-08-09 | 2005-06-01 | Astrazeneca AB | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| BRPI0412426A (pt) * | 2003-07-10 | 2006-09-05 | Astrazeneca Ab | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| WO2007003933A2 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
| EP1971338B8 (en) * | 2005-12-22 | 2011-09-21 | AstraZeneca AB | Combination of zd6474 and pemetrexed |
| US20100092466A1 (en) * | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
| US20100212978A1 (en) * | 2009-02-23 | 2010-08-26 | Wen-Hung Huang | Bicycle with two operation molds |
-
2002
- 2002-10-09 GB GBGB0223380.7A patent/GB0223380D0/en not_active Ceased
-
2003
- 2003-10-06 NZ NZ538999A patent/NZ538999A/en not_active IP Right Cessation
- 2003-10-06 SI SI200330784T patent/SI1551409T1/sl unknown
- 2003-10-06 AT AT03751032T patent/ATE357236T1/de active
- 2003-10-06 DE DE60312715T patent/DE60312715T2/de not_active Expired - Lifetime
- 2003-10-06 PT PT03751032T patent/PT1551409E/pt unknown
- 2003-10-06 JP JP2004542620A patent/JP5416328B2/ja not_active Expired - Fee Related
- 2003-10-06 EP EP03751032A patent/EP1551409B1/en not_active Expired - Lifetime
- 2003-10-06 CN CNB2003801011766A patent/CN100363004C/zh not_active Expired - Fee Related
- 2003-10-06 ES ES03751032T patent/ES2282656T3/es not_active Expired - Lifetime
- 2003-10-06 US US10/530,567 patent/US20060009418A1/en not_active Abandoned
- 2003-10-06 DK DK03751032T patent/DK1551409T3/da active
- 2003-10-06 KR KR1020057005960A patent/KR101098061B1/ko not_active Expired - Fee Related
- 2003-10-06 AU AU2003269253A patent/AU2003269253B2/en not_active Ceased
- 2003-10-06 MX MXPA05003595A patent/MXPA05003595A/es active IP Right Grant
- 2003-10-06 BR BR0315088-7A patent/BR0315088A/pt not_active IP Right Cessation
- 2003-10-06 WO PCT/GB2003/004334 patent/WO2004032937A1/en not_active Ceased
- 2003-10-06 CA CA2501651A patent/CA2501651C/en not_active Expired - Fee Related
-
2005
- 2005-03-24 IL IL167633A patent/IL167633A/en active IP Right Grant
- 2005-03-29 NO NO20051575A patent/NO330601B1/no not_active IP Right Cessation
-
2006
- 2006-01-17 ZA ZA200502753A patent/ZA200502753B/en unknown
-
2007
- 2007-05-17 CY CY20071100670T patent/CY1106601T1/el unknown
-
2009
- 2009-08-14 US US12/541,647 patent/US20100120708A1/en not_active Abandoned
-
2010
- 2010-12-24 JP JP2010287659A patent/JP2011088921A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006504723A5 (enExample) | ||
| JP2005511597A5 (enExample) | ||
| JP2006500346A5 (enExample) | ||
| CA2501651A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| JP2008514577A5 (enExample) | ||
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| JP2005530735A5 (enExample) | ||
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
| WO2006035204A3 (en) | Combination comprising zd6474 and an imatinib | |
| DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
| WO2004071397A3 (en) | Combination therapy of zd6474 with 5-fu or/and cpt-11 | |
| NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
| CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| NO20064755L (no) | Kombinasjonsterapi | |
| JP2011500650A5 (enExample) | ||
| BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
| WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine | |
| ATE429435T1 (de) | 7h-pyrrolopyrimidinderivate | |
| JP2007538066A5 (enExample) | ||
| DE60308403D1 (de) | Kombinationstherapie mit gemzitabin und zd6126 |